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Abstract 
Background: Mitochondrial diseases are difficult to diagnose and treat. Recent advances in genetic diagnostics and 
more effective treatment options can improve patient diagnosis and prognosis, but patients with mitochondrial dis‑
ease typically experience delays in diagnosis and treatment. Here, we describe a unique collaborative practice model 
among physicians and scientists in Spain focused on identifying TK2 deficiency (TK2d), an ultra‑rare mitochondrial 
DNA depletion and deletions syndrome.
Main Body: This collaboration spans research and clinical care, including laboratory scientists, adult and pediatric 
neuromuscular clinicians, geneticists, and pathologists, and has resulted in diagnosis and consolidation of care for 
patients with TK2d. The incidence of TK2d is not known; however, the first clinical cases of TK2d were reported in 2001, 
and only ~ 107 unique cases had been reported as of 2018. This unique collaboration in Spain has led to the diagnosis 
of more than 30 patients with genetically confirmed TK2d across different regions of the country. Research affiliate 
centers have led investigative treatment with nucleosides based on understanding of TK2d clinical manifestations 
and disease mechanisms, which resulted in successful treatment of a TK2d mouse model with nucleotide therapy 
in 2010. Only 1 year later, this collaboration enabled rapid adoption of treatment with pyrimidine nucleotides (and 
later, nucleosides) under compassionate use. Success in TK2d diagnosis and treatment in Spain is attributable to two 
important factors: Spain’s fully public national healthcare system, and the designation in 2015 of major National Refer‑
ence Centers for Neuromuscular Disorders (CSURs). CSUR networking and dissemination facilitated development of a 
collaborative care network for TK2d disease, wherein participants share information and protocols to request approval 
from the Ministry of Health to initiate nucleoside therapy. Data have recently been collected in a retrospective 
study conducted under a Good Clinical Practice–compliant protocol to support development of a new therapeutic 
approach for TK2d, a progressive disease with no approved therapies.
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Background
Patients with rare mitochondrial disorders predomi-
nantly manifesting with muscle symptoms experience 
long diagnostic odysseys [1–4]. Most patients with mito-
chondrial myopathies will see an average of eight physi-
cians over 8–10  years before receiving a diagnosis [4]. 
For patients with rapidly progressing, severe disease, this 
delay between onset of symptoms and initiation of treat-
ment could be fatal or could result in significant morbid-
ity [2].
Spain has been uniquely successful in identifying and 
treating patients with thymidine kinase 2 deficiency 
(TK2d), an ultra-rare, autosomal recessive mitochon-
drial DNA (mtDNA) depletion and deletions syndrome 
(MDDS). A collaborative partnership, mainly between 
research centers at the Vall d’Hebron Research Institute 
(VHIR) in Barcelona (Spain) and Columbia University 
Irving Medical Center (CUIMC) in New York City (USA), 
has facilitated understanding of disease pathology and 
the development of oral nucleosides as potential therapy 
[5]. Spain continues to lead in identification, diagnosis, 
and treatment of patients with TK2d due to collabora-
tion and networking through the Spanish National Ref-
erence Centers for Neuromuscular Disorders (CSURs). 
Here, we describe our experience in TK2d to exemplify 
how CSURs can shorten the diagnostic odyssey and con-
solidate patient care for a rare mitochondrial disease that 
requires coordination of highly specialized, multidiscipli-
nary care teams to improve patient outcomes and quality 
of life.
The objective of this work is to illustrate how CSURs in 
Spain (1) coordinate research, diagnosis, and treatment 
efforts within the framework of the Spanish National 
Health System (SNS), (2) optimize access to care for 
patients with TK2d, and (3) could serve as a model for 
diagnosis and treatment of patients with rare neuromus-
cular diseases throughout the EU.
Main body
Treatment of TK2d and rare neuromuscular disease 
in Spain: the importance of reference centers
In 2015, the Spanish Ministry of Health designated a net-
work of National Reference Centers (CSURs) for Neu-
romuscular Disorders by Real Decreto 1302/2006. The 
TK2d experience in Spain is a uniquely successful exam-
ple of a rare disease that has been diagnosed and treated 
within the CSUR framework [6]. Diagnosis and care for 
patients with rare diseases are most efficiently organ-
ized in reference centers, which can provide specialized 
assistance, ensure equity of access to care [1], and con-
tribute to gathering and dissemination of knowledge [2]. 
In Spain, CSURs-NMD have simplified and streamlined 
the referral and diagnostic process. Referrals of patients 
with TK2d and other mitochondrial myopathies among 
national Units of Neuromuscular Disorders within the 
SNS facilitate rapid identification, diagnosis, and treat-
ment of patients.
TK2 deficiency disease: clinical features
TK2d is characterized by progressive muscle weakness, 
with predominant distribution in the proximal, bul-
bar, and facial muscles together with severe respiratory 
involvement [7–10]. Age of onset and rate of progression 
are quite variable, but in all its clinical forms, TK2d clini-
cal manifestations can include proximal muscle weak-
ness, dysphagia, and respiratory insufficiency, leading 
to premature death in a majority of patients [7, 8, 11]. 
As is the case for most rare diseases, TK2d is probably 
underdiagnosed. Approximately 107 molecularly con-
firmed cases were reported worldwide in the published 
literature as of 2018 [11], but TK2d incidence is probably 
underestimated due to early mortality and misdiagno-
ses [3]. Given the progressive nature of the disease and 
the availability of effective therapy with oral nucleosides, 
earlier identification, diagnosis, and treatment are criti-
cal to patient prognosis, survival, and functionality in the 
motor, respiratory, and feeding domains [7, 8, 10, 12, 13].
Collaborative care model in Spain: focus on TK2d
The collaborative care model in Spain has identified and 
treated the largest cohort of patients worldwide: ~ 30 of 
the ~ 107 total TK2d cases were diagnosed and treated in 
Spain (~ 30%). In Spain, most patients with genetic myo-
pathies are referred to CSURs for neuromuscular disor-
ders (CSURs-NMD) for diagnosis and treatment through 
national neuromuscular units (Fig. 1) [1, 6]. The network 
of CSURs-NMD throughout Spain coordinate with the 
Spanish collaboration among national Units of Neuro-
muscular Disorders to facilitate identification and homo-
geneous treatment (Fig.  2). CSURs-NMD at Hospital U 
12 Octubre (H12O) in Madrid and Hospital U Virgen 
del Rocío (HUVR) in Sevilla were pioneers in coordinat-
ing the process to harmonize research, clinical care, and 
management of TK2d cases.
Conclusions: The Spanish experience in diagnosis and treatment of TK2d is a model for the diagnosis and develop‑
ment of new treatments for very rare diseases within an existing healthcare system.
Keywords: Mitochondrial disease, Mitochondrial medicine, Thymidine kinase 2 deficiency (TK2d)
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Diagnosis and treatment paradigms within the CSUR 
framework integrate ongoing research and develop-
ment activities into clinical practice. Collaboration 
occurs between local centers and CSURs within a 
regional network, which connects to the larger, national 
CSUR network. CSURs-NMD further coordinate with 
research affiliates in Spain (Center for Biomedical Net-
work Research on Rare Diseases [CIBERER], Center for 
Biomedical Network Research on Neurodegenerative 
Disorders [CIBERNED], Institute of Biomedicine in 
Seville [IBiS], Research Institute Hospital 12 de Octubre 
[imas12], VHIR). Neuromuscular disease specialists pro-
vide expert opinion on obtaining differential diagnosis of 
TK2d, including recommendations for additional test-
ing. CSURs develop clinical protocols and provide treat-
ment for TK2d through clinical trials and compassionate 
use programs to ensure timely access to care. CSURs-
NMD, as part of the wider EURO-NMD, also disseminate 
Fig. 1 Collaboration among major reference centers across regions of Spain and research affiliates
Fig. 2 Role of the CSURs in coordinating research, diagnosis, clinical care, and information dissemination
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information and house registries for international access. 
Although no archival registry of genetic mutations in 
TK2d is available, patients with TK2d and their caregiv-
ers are invited to join the TK2d patient registry (https:// 
www. tk2d. com/) to facilitate networking and data dis-
semination. CSURs consolidate expertise to provide 
care of the highest standard for affected individuals. In 
the case of TK2d, the Spanish collaboration and CSURs-
NMD allowed rapid transition of targeted nucleoside 
therapy through the development pipeline by coordinat-
ing preclinical and clinical research activities, including 
the recent Good Clinical Practice (GCP)-compliant ret-
rospective protocol. Ongoing research initiatives seek to 
optimize patient treatment strategies (NCT03845712; 
NCT03701568). Notably, of 38 total patients enrolled, 23 
patients were from Spain (60%). Four of the eight (50%) 
participating sites were from the collaboration, and 
patients are continuing to receive nucleoside therapy.
Key milestones in TK2d diagnosis and treatment: role 
of CSURs‑NMD and Spanish research affiliates
Clinicians and scientists at VHIR (Spain) and CUIMC 
(USA) have collaboratively contributed to TK2d research 
and development since the first TK2d patients were 
described in 2001 [14, 15] (Fig.  3). The collaboration 
represents a critical mass of individuals with multidis-
ciplinary expertise to interpret clinical findings and to 
propose and test effective treatment modalities for TK2d 
and other mitochondrial disorders. Within 2 years of the 
first reported TK2d cases [14, 15], mitochondrial disease 
researchers at CUIMC characterized genetic and clinical 
features of TK2d and described its pathogenesis [16, 17]. 
TK2d is caused by mutations and deletions in the TK2 
gene on chromosome 16q21 in nuclear DNA. More than 
30 pathogenic variants in the TK2 gene have been iden-
tified, most of which are missense mutations (70%) [11] 
and result in loss of function of the TK2 enzyme, which 
phosphorylates deoxythymidine (dT) and deoxycy-
tidine (dC) to deoxythymidine monophosphate (dTMP) 
and deoxycytidine monophosphate (dCMP), respec-
tively (Fig.  4). These deoxynucleoside monophosphates 
are consecutively phosphorylated to the deoxynucleo-
side triphosphates (dNTPs) necessary for replication of 
mtDNA [11]. Ensuing mtDNA depletion/multiple dele-
tions lead to inadequate production of mitochondrial 
respiratory chain complexes needed for mitochondrial 
oxidative phosphorylation, the main source of cellular 
energy [18]. Genotype–phenotype correlations were 
characterized in two mouse models of TK2d. Research-
ers at CUIMC developed a TK2 H126N knockin mouse 
model of TK2d based on observed clinical pathogenic 
phenotypes [19, 20]. That same year, Swedish researchers 
independently characterized a TK2 knockout (TK2−/−) 
mouse model [21]. Phenotype in the mouse models 
recapitulated clinical presentation of severe mtDNA 
depletion in skeletal muscle, leading to mitochondrial 
myopathy. Taken together, these data delineated the 
pathogenesis of TK2d and suggested targeted nucleoside 
therapy as a plausible treatment modality to restore mito-
chondrial function by restoring available pools of dNTPs.
Proof-of-concept using nucleotide therapy was first 
published in mouse models in 2014 [22], paving the way 
for establishing dCMP/dTMP as the first effective phar-
macologic treatment strategy for TK2d in human clinical 
studies [12]. The preclinical results with dTMP/dCMP 
in TK2-deficient mice encouraged treatment of the first 
Spanish patient with dTMP/dCMP, and soon thereafter 
a second patient was treated in the USA [5, 12]. Further 
Fig. 3 Key milestones in TK2d diagnostics and treatment: role of the Spanish research affiliates and collaborators [7, 10, 14]
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studies demonstrated that, when administered orally, the 
active compounds are not the monophosphates dTMP/
dCMP, but the corresponding nucleosides dT/dC [5, 23]. 
Pharmacologically, nucleoside therapy restores mito-
chondrial function through both a cytosolic nucleoside 
salvage pathway and residual TK2 activity within the 
mitochondria (see Fig. 4). Approval for the use of nucleo-
sides in humans under compassionate use by the Spanish 
Drug Agency (AEMPS), driven by CSURs-NMD at H12O 
and HUVR, led to treatment of approximately 30 patients 
in Spain between 2014 and 2018 [5, 12]. These clinical 
data demonstrate the efficacy of nucleoside therapy in 
slowing or reversing disease progression and prolong-
ing survival among patients with TK2d internationally, 
with more than 40 individuals currently under treat-
ment in the USA, Central and South America, Eastern 
Europe, and Asia. Nucleoside therapy was licensed with 
industry stakeholders in 2016, based on patented intel-
lectual property with Columbia University and the VHIR. 
PRIME (PRIorityMEdicines) designation was granted by 
the EMA in 2018 for the product under development, 
MT1621, which is a combination product of two nucle-
osides, deoxycytidine (dC) and deoxythymidine (dT), 
intended as a nucleoside therapy via a calculated dose of 
combination product (dC/dT) for the treatment of TK2d 
(Fig.  4). MT1621 was granted Orphan Drug designa-
tion by both the US-FDA and the EMA. Breakthrough 
Therapy Designation was granted by the US-FDA. Clini-
cal studies are under way to obtain regulatory approval 
for worldwide availability of MT1621 for patients with 
TK2d.
In parallel with drug development, three seminal 
papers describing the natural history of TK2d were 
published in 2018 and 2019 (Fig.  3). These papers rep-
resented important milestones in characterizing the nat-
ural history of TK2d. Case study and case series reports 
published over approximately 2 decades were consoli-
dated into the two 2018 publications describing the clini-
cal phenotype and spectrum of disease [8, 10]. A year 
later, as a consequence of Spanish success in identifying 
TK2d patients, Domínguez-González et  al. published a 
description of late-onset TK2d based on 18 patients, 16 
of whom were identified in Spain. The late-onset form, 
which accounted for about 20% of cases, was first identi-
fied in 2010 as a slower progressing form of disease [11]. 
Improved genetic testing enabled the characterization of 
late-onset TK2d in 2013 [24]. These papers led to pub-
lication of the first proposed diagnostic and treatment 
algorithms [7, 8, 10, 11].
Diagnosis
Detailed characterization of the natural history of TK2d 
has informed diagnostic algorithms and improved diag-
nostic accuracy within the CSUR framework in Spain. 
Fig. 4 Pharmacological mechanism of nucleoside therapy in TK2d. MT1621 (dC/dT) deoxynucleosides drive production of dTMP and dCMP from 
the enzymes thymidine kinase 1 (TK1) and deoxycytidine kinase (dCK), respectively, which cross the mitochondrial membrane to provide substrate 
for dTTP and deoxycytidine triphosphate (dCTP) production in mtDNA synthesis and replication [23]. Both mechanisms help to restore the available 
pool of mtDNA for oxidative phosphorylation and energy production
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Typically, patients with TK2d in Spain would initially 
present to their primary care physician, but general prac-
titioners cannot directly refer patients to CSURs. Patients 
presenting with muscle weakness are first referred to the 
general neurology unit or to a neuromuscular neurolo-
gist at a local center. If patients do not receive a defini-
tive diagnosis, or if the case shows high complexity, then 
patients with myopathy are referred to a CSUR-NMD. An 
appointment is scheduled within 15  days after a simple 
form is filled out to indicate referral to a CSUR.
TK2d typically manifests as pure muscle weakness, 
a tissue-specific phenotype that is quite different from 
most infantile mitochondrial syndromes that exhibit mul-
tisystemic involvement and are usually referred to CSURs 
for inborn metabolism errors. Therefore, in our experi-
ence in Spain, patients with TK2d are identified for the 
first time in neuromuscular units, where a muscle biopsy 
is frequently performed to guide the diagnosis of patients 
with muscle symptoms. In patients with TK2d, the biopsy 
confirms the mitochondrial origin of the disorder, thus 
directing the subsequent genetic study. If a muscle biopsy 
is not performed, the use of next-generation sequencing 
(NGS) approaches using phenotype-driven gene panels 
(many of which do not include the TK2 gene) may focus 
attention on analysis of genes involved in non-mitochon-
drial myopathies and muscle dystrophies, consequently 
not reaching the diagnosis. However, as the use of whole 
exome sequencing (or, in the future, whole genome 
sequencing) becomes more widespread, diagnosis may 
be reached via these techniques alone [11, 25]. Once the 
TK2 gene has been implicated and a diagnosis of TK2d is 
in place, a muscle biopsy or assessment in other tissues 
(e.g., urine epithelial cells, fibroblasts, white blood cells) 
is not mandatory because the associated metrics (e.g., 
respiratory chain analysis, mtDNA quantification, TK2 
activity from skeletal muscle biopsy specimens) are not 
essential for management of the disease [7, 26]. Circulat-
ing biomarkers such as GDF-15 and/or FGF-21 may also 
complement molecular and genetic diagnoses, as these 
metrics provide additional information about monitoring 
disease progression and pharmacodynamic response to 
treatment [27].
Occasionally, a patient is diagnosed with mitochondrial 
myopathy due to muscle biopsy findings, with no deeper 
exploration into the genetic cause. This could be attrib-
uted to the fact that reaching an accurate genetic diag-
nosis is not easy in the field of mitochondrial disorders 
(including those manifesting with myopathy) because of 
involvement of more than 300 genes encoded by nuclear 
and mitochondrial genomes [28]. Furthermore, this 
approach has been favored due to lack of treatments 
for these disorders, but the availability of new disease-
modifying therapies has changed the diagnostic and 
therapeutic landscapes by introducing disease-tailoring 
therapies that require identification of a genetic defect 
[29].
Currently, access to genetic studies in the SNS is widely 
available; hence, we sometimes find patients with mito-
chondrial disease who are referred from the local neu-
romuscular unit to the CSUR-NMD unit after already 
receiving a genetic diagnosis. On the other hand, when 
a referring physician sends a muscle sample to a labora-
tory with expertise in mitochondrial diseases, the entire 
diagnostic process, including thorough genetic testing 
(i.e., both mtDNA and nuclear encoded gene analysis), is 
performed without the need for the referring doctor to 
specify the tests to be performed. This makes it easier for 
a definitive genetic diagnosis to be reached, even if the 
doctor sending the sample is not an expert in mitochon-
drial diseases.
Clinical guidelines specific to TK2d are under develop-
ment, but an operational diagnostic algorithm is in place 
at reference centers in Spain based on consolidation of all 
published case reports and case series, harmonized with 
guidelines recommended by the EURO-NMD Muscle 
Diseases and Mitochondrial Diseases Working Groups 
(Fig.  5, upper panel) [11, 30–32]. Identification of TK2 
as a causative gene has enabled genetic approaches to 
molecular diagnosis, including whole exome sequenc-
ing, in addition to the mitochondrial diagnostic panel of 
genes related to mtDNA maintenance after signs of mito-
chondrial dysfunction are detected on muscle biopsy [4, 
15, 30, 32, 33].
Monitoring and treatment
Patients with TK2d require multidisciplinary care. Ref-
erence centers play a crucial role in optimizing access to 
care [1]. After confirming a diagnosis, CSURs consolidate 
resources to optimize patient access to care [2, 6] (Fig. 5, 
lower panel). CSURs consolidate care teams and link 
patients with appropriate specialists, including physical 
therapists, speech therapists, pulmonologists, metabolic 
specialists, and neuromuscular specialists [11, 30, 32]. 
Consolidating care within the CSUR framework harmo-
nizes patient care, minimizing the number of appoint-
ments and time lost from work for the primary caregiver 
while avoiding contradictory recommendations. CSURs 
also play a pivotal role in patient education, including 
genetic counseling for parents, siblings, and prospective 
parents with late-onset TK2d. CSURs can recommend 
patient associations for psychosocial and emotional sup-
port for patients and their caregivers and families.
Equity of access
The SNS is fully public, which represents a crucial 
aspect of care for patients with TK2d and other rare 
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mitochondrial myopathies. Ensuring equity of access to 
care removes any economic or social barriers that could 
hinder access of certain patients to the healthcare system 
and to highly specialized CSURs [6]. The SNS facilitates 
universal and free access to specialists of any discipline, 
along with complementary testing and therapeutic pro-
cedures for any Spanish citizen and everyone holding 
the Spanish Health Card. The Spanish population is well 
accustomed to this universal characteristic of the Spanish 
Health System, established in the early 1970s. As such, 
there is little hesitation in obtaining medical consulta-
tions on any health problem.
Limitations
In explaining the high rate of identification of TK2d 
patients in Spain without additional exploratory stud-
ies, it is difficult to rule out completely the possibility of 
a genetic predisposition or founder effect. However, a 
founder effect is unlikely, given that patients carry dif-
ferent mutations, both homozygous and compound 
heterozygous [8, 10]. Further, TK2d does not appear to 
have an ethnic predisposition, although the p.Lys202del 
mutation, which is the most frequently reported muta-
tion in late-onset cases so far, has been identified only in 
Spanish patients and patients of Hispanic ethnic back-
ground [7]. Finally, carrier frequency by exome analysis 
is currently unknown in Spain or elsewhere in the world. 
Thus, disease frequency cannot be accurately estimated 
or compared to diagnostic effectiveness in Spain.
Conclusions
The Spanish collaborative model supports the develop-
ment of a new therapeutic approach for TK2d, a pro-
gressive, ultra-rare disease with no approved therapies. 
Success in TK2d early identification, diagnosis, and 
treatment in Spain is attributable to (1) Spain’s fully Pub-
lic National Healthcare System, which enables equity of 
access to care, and (2) the designation of CSURs-NMD, 
which homogenize a highly specialized diagnostic pro-
cess, including muscle biopsy and molecular study. Uni-
versal and free access to genetic studies ensures that 
a detailed understanding of the genetic causes of mito-
chondrial disease is more available than in countries with 
private healthcare systems. The Spanish experience in 
diagnosis and treatment of TK2d is a model for the diag-
nosis and development of new treatments for very rare 
diseases within an existing healthcare system.
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